Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.

Although a clear trend is apparent for the association between the V98L variant of AnxA2 and lower circulating PCSK9 levels, more patients need to be screened for AnxA2 mutations before definitive conclusions can be reached on the protective properties of these possible GOF mutations and their relationship to statin response.

also in 19,460 other papers